FDA Clearance Tracker · K250971
Embosphere Microspheres
Last checked: Nov 20, 2026Latest source record: May 16, 2025 (this decision)Source: openFDAMethods & limitations
Decided
May 16, 2025
Substantially Equivalent
Time to decision
46 days
Received Mar 31, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K250971
- Device name
- Embosphere Microspheres
- Applicant
- Biosphere Medical, S.A.
- Applicant location
- Roissy-En-France, FR
- Received
- Mar 31, 2025
- Decided
- May 16, 2025
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 870.3300
- Specialty
- CardiologyInterventional Cardiology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code KRD. The earliest in FDA's data is P780011, decided May 15, 1980.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K250971
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Biosphere Medical, S.A.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Torpedo Gelatin Foam510(k)
K192480 · Decided Nov 21, 2019 · 72 days after receipt
Device type: Device, Vascular, For Promoting Embolization (KRD) · Cardiology
K183120 · Decided Aug 6, 2019 · 270 days after receipt
Device type: Device, Vascular, For Promoting Embolization (KRD) · Cardiology
- Torpedo Gelatin Foam510(k)
K183578 · Decided Jun 18, 2019 · 179 days after receipt
Device type: Device, Vascular, For Promoting Embolization (KRD) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.